Abstract:BACKGROUNDPatients with acute ischemic stroke and large artery occlusive disease (LAOD) have an increased risk for early neurologic deterioration (END) due to progressive stroke, early recurrent ischemic stroke(ERIS), or symptomatic intracranial cerebral hemorrhage(SICH). Low-molecular-weight heparin (LMWH)has been widely advocated to prevent venous thromboembolism,but its risks and benefits in early ischemic stroke are inadequately defined.OBJECTIVETo determine the efficacy and safety of LMWH in treating END in patients with acute ischemic stroke and LAOD.DESIGNPost hoc analysis of randomized, controlled trial.SETTINGAcademic research.PATIENTSAmong 603 patients recruited, 353 patients(180 treated with LMWH, 173 with aspirin) had acute ischemic stroke and LAOD.INTERVENTIONSPatients were randomly assigned to receive either subcutaneous LMWH or oral aspirin within 48 hours after stroke onset for 10 days, then all received aspirin once daily for 6 months.MAIN OUTCOME MEASURESWe assessed whether LMWH was superior to aspirin for the prevention of END within the first 10 days after index stroke. Early neurologic deterioration was defined as a composite end point of progressive stroke, ERIS, and SICH.RESULTSAmong 353 patients included in the study, END within the first 10 days occurred in 6.7% of LMWH allocated patients (12 of 180 patients) compared with 13.9% of aspirin-allocated patients (24 of 173). Low molecular-weight heparin was significantly associated with the reduction of END(absolute risk reduction, 7.2%; odds ratio [OR], 0.44; 95% CI, 0.21-0.92). When individual components of END were examined, LMWH was significantly associated with a lower frequency of stroke progression within the first 10 days compared with aspirin(5.0% [9 of 180] vs 12.7% [22 of 173]; OR, 0.36; 95%CI, 0.16-0.81). Meanwhile, among those taking LMWH vs aspirin, the frequency rates of ERIS were 1.1% (2 of 180) vs 0 (0); 0.6% (1 of 180) vs 1.2% (2 of 173) for SICH;and 2.2% (4 of 180) vs 2.9% (5 of 173) for symptomatic and asymptomatic cerebral hemorrhage, respectively; they showed nonsignificant trends. Early neurologic deterioration was significantly associated with 6-month disability with both LMWH(OR, 12.75; 95% CI, 3.27-49.79 on Barthel Index and OR, 18.15; 95% CI, 2.09-157.93 on modified Rankin Scale) and aspirin (OR, 6.09; 95% CI,2.44-15.20 on Barthel Index and OR, 7.50; 95% CI, 2.08-27.04 on modified Rankin Scale) groups.CONCLUSIONSFor patients with acute ischemic stroke and LAOD, treatment with LMWH within 48 hours of stroke may reduce END during the first 10 days, mainly by preventing stroke progression. The similar rate of cerebral hemorrhage between LMWH and aspirin demonstrated that LMWH may be safely used in acute ischemic stroke.TRIAL REGISTRATIONstroke center.org/trials Identifier: FISS -tris

Amelioration of motor function with low-molecular weight heparin in patients with acute cerebral infarction

A study on application value of susceptibility weighted imaging combined with platelet distribution width in intravenous thrombolysis for treatment of patients with acute cerebral infarction

Comparison of Low-Molecular-weight-heparin and Unfractionated Heparin for Acute PTE

Effect and safety of rt-PA combined with Hydroxyethyl starch in the treatment of acute cerebral infarction

Non-atrial Fibrillation Was Associated with Early Neurological Improvement after Intravenous Thrombolysis with Rt-Pa in Patients with Acute Ischemic Stroke

Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Low-molecular-weight heparin in the prevention of venous thromboembolism among patients with acute intracerebral hemorrhage: A meta-analysis

Low-molecular-weight heparin reduces the formation of lower limb deep venous thrombosis in patients with hypertensive intracerebral hemorrhage

Low-Molecular-Weight Heparin Versus Aspirin for Acute Ischemic Stroke with Large Artery Occlusive Disease

Meta-Analysis of the Effectiveness and Safety of Intravenous Thrombolysis in Patients with Acute Cerebral Infarction

Low-molecular-weight Heparin and Early Neurologic Deterioration in Acute Stroke Caused by Large Artery Occlusive Disease.

Efficacy and Safety Study on Low Molecular Heparin in the Prevention for Venous Thromboembolism Prophylaxis after Spontaneous Intracerebral Hemorrhage

Curative effect of intravenous thrombolytic therapy with recombinant tissue plasminogen activator on acute cerebral infarction patients with or without atrial fibrillation

Evaluation of efficacy and safety of Reteplase and Alteplase in the treatment of hyper-acute cerebral infarction.

Effects of low molecular weight heparin combined with hyperbaric oxygen on neurologic function and coagulation factors in patients with intracranial venous thrombosis

The therapeutic effect of low molecular weight heparin on patients with unstabl e angina pectoris

Efficacy of Thrombolysis by Intravenous Recombinant Tissue Plasminogen Activator in Hyperacute Cerebral Infarction

Low-Molecular-Weight Heparin Versus Aspirin For Acute Ischemic Stroke With Large Artery Occlusive Disease Subgroup Analyses From The Fraxiparin In Stroke Study For The Treatment Of Ischemic Stroke (Fiss-Tris) Study

Changes of plasma biomolecules in patients with acute cerebral infarction before and after treatment

Effect of Argatroban Injection on Clinical Efficacy in Patients with Acute Cerebral Infarction: Preliminary Findings

Clinical Study the Effects of Lumbrukinase for Treatment of Acute Cerebral Infarction